Global New Drug Delivery Systems Market 2022-2026
Technavio has been monitoring the new drug delivery systems market and it is poised to grow by $ 77.29 bn during 2022-2026, progressing at a CAGR of 6.08% during the forecast period. Our report on the new drug delivery systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of chronic diseases, growth in the biologics market, and digitalization in the healthcare system. In addition, the rising prevalence of chronic diseases is anticipated to boost the growth of the market as well.
The new drug delivery systems market analysis includes the route of administration segment and geographic landscape.
Technavio's new drug delivery systems market is segmented as below:
By Route of Administration
- Oral drug delivery systems
- Injectable drug delivery systems
- Pulmonary drug delivery systems
- Transdermal drug delivery systems
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the rising prevalence of chronic diseases as one of the prime reasons driving the new drug delivery systems market growth during the next few years. Also, growth in the biologics market and digitalization in the healthcare system will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on new drug delivery systems market covers the following areas:
- New drug delivery systems market sizing
- New drug delivery systems market forecast
- New drug delivery systems market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading new drug delivery systems market vendors that include Abbott Laboratories, Amgen Inc., AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gerresheimer AG, Gilead Sciences Inc., Kindeva Drug Delivery L.P., Medtronic Plc, Merck KGaA, Nemera, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services Inc., Ypsomed Holding AG, and Antares Pharma Inc. Also, the new drug delivery systems market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Companies MentionedAbbott Laboratories, Amgen Inc., AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gerresheimer AG, Gilead Sciences Inc., Kindeva Drug Delivery L.P., Medtronic Plc, Merck KGaA, Nemera, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services Inc., Ypsomed Holding AG, Antares Pharma Inc.